BAY94-8862

DRUG3 trials

Sponsors

Bayer

Conditions

Diabetic NephropathiesHeart Failure

Phase 2

BAY94-8862 Dose Finding Trial in Subjects With Chronic Heart Failure and Mild (Part A) or Moderate (Part B) Chronic Kidney Disease

CompletedNCT01345656

BayerHeart Failure

Start: 2011-05-09End: 2012-07-16Updated: 2022-02-10

Phase IIb Safety and Efficacy Study of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Moderate Chronic Kidney Disease Alone

CompletedNCT01955694

BayerHeart Failure

Start: 2013-11-11End: 2015-02-20Updated: 2021-07-16

Safety and Efficacy of Different Oral Doses of BAY94-8862 in Japanese Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy (ARTS-DN Japan)

CompletedNCT01968668

BayerDiabetic Nephropathies

Start: 2013-10-28End: 2014-11-07Updated: 2021-07-16

Related Papers

Population Pharmacokinetic and Exposure-Response Analysis of Finerenone: Insights Based on Phase IIb Data and Simulations to Support Dose Selection for Pivotal Trials in Type 2 Diabetes with Chronic Kidney Disease.

2020-03-0124 citations

Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease.

2012-05-0475 citations